AMPA receptor antagonists: potential therapeutic applications.
The current review will focus on the recent patents for AMPA receptor antagonists and their claims, evidence for their therapeutic effectiveness in the treatment of epilepsy and their potential role in psychiatric and neurodegenerative disorders. It will also highlight the proposed mechanisms of action and the implications thereof for our current understanding of the biomolecular basis of these pathologies. It will conclude with a summary of what we know, but also point out the remaining uncertainties, especially as this relates to the claims in the patent under discussion.
Mattes
Henri
H
Novartis Institute for Biomedical Research, Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland. henri.mattes@novartis.com
Lingenhoehl
Kurt
K
Kalkman
Hans
H
Auberson
Yves
Y
Renaud
Johanne
J
Schmutz
Markus
M
Orain
David
D
D000818:Animals; D001008:Anxiety Disorders / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000494:pharmacology; D010146:Pain / Q000188:drug therapy; D010330:Patents as Topic; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*; D012559:Schizophrenia / Q000188:drug therapy
D018696:Neuroprotective Agents; D018091:Receptors, AMPA